Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Neuro-oncology. 2018 Feb 8. pii: 4843984. doi: 10.1093/neuonc/noy020
    Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.
    Aldape K1,  Amin SB2,  Ashley DM3,  Barnholtz-Sloan JS4,  Bates AJ5,  Beroukhim R6,  Bock C7,  Brat DJ8,  Claus EB9,  Costello JF10,  de Groot JF11,  Finocchiaro G12,  French PJ13,  Gan HK14,  Griffith B15,  Herold-Mende CC16,  Horbinski C17,  Iavarone A18,  Kalkanis SN19,  Karabatsou K20,  Kim H21,  Kouwenhoven MCM22,  McDonald KL23,  Miletic H24,  Nam DH25,  Ng HK26,  Niclou SP27,  Noushmehr H28,  Ormond R29,  Poisson LM30,  Reifenberger G31,  Roncaroli F32,  Sa JK33,  Sillevis Smitt PAE34,  Smits M35,  Souza CF36,  Tabatabai G37,  Van Meir EG38,  Verhaak RGW39,  Watts C40,  Wesseling P41,  Woehrer A42,  Yung WKA43,  Jungk C44,  Hau AC45,  van Dyck E46,  Westerman BA47,  Yin J48,  Abiola O49,  Zeps N50,  Grimmond S51,  Buckland M52,  Khasraw M53,  Sulman EP54,  Muscat AM55,  Stead L56
    Author information
    1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
    2Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA.
    3Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, USA.
    4Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
    5National Brain Tumor Society, Newton, MA, USA.
    6Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
    7CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
    8Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
    9Yale School of Public Health, New Haven, CT, and Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
    10University of California San Francisco, San Francisco, CA, USA.
    11University of Texas, MD, and Anderson Cancer Center, Houston, TX, USA.
    12Fondazione IRCCS Istituto Neurologico Besta, Milano, Italy.
    13Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
    14Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.
    15Department of Radiology, Henry Ford Health System, Detroit, MI, USA.
    16Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany.
    17Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
    18Department of Neurology, Department of Pathology, Institute for Cancer Genetics, Columbia University Medical Center, New York, USA.
    19Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
    20Salford Royal Hospital, Stott Lane, Greater Manchester, UK.
    21Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA.
    22Department of Neurology, VU University Medical Center/Brain Tumor Center, Amsterdam, The Netherlands.
    23Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Sydney, Australia.
    24Department of Pathology, Haukeland University Hospital, Bergen, Norway.
    25Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    26Department of Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
    27Luxembourg Institute of Health, NorLux Neuro-Oncology Laboratory, Luxembourg.
    28Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
    29Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA.
    30Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
    31Department of Neuropathology, Heinrich Heine University Duesseldorf Medical Faculty, Duesseldorf, Germany.
    32Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, UK.
    33Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
    34Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
    35Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
    36Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
    37Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, University Hospital, Tübingen, Germany.
    38Departments of Neurosurgery, Hematology, and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    39Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA.
    40Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, UK.
    41Department of Pathology, VU University Medical Center/Brain Tumor Center Amsterdam, Amsterdam, The Netherlands, and Princess Máxima Center for Pediatric Oncology and University Medical Center Utrecht, The Netherlands.
    42Institute of Neurology, Medical University of Vienna, Vienna, Austria.
    43Anderson Cancer Center, Houston, TX, USA.
    44Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany.
    45Luxembourg Institute of Health, NorLux Neuro-Oncology Laboratory, Luxembourg.
    46Luxembourg Institute of Health, NorLux Neuro-Oncology Laboratory, Luxembourg.
    47Brain Tumor Center Amsterdam, Cancer Center Amsterdam, VU Medical Center, Amsterdam, The Netherlands.
    48Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Australia.
    49Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA.
    50Monash University and Epworth Health, Melbourne, Victoria, Australia.
    51University of Melbourne and Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.
    52Royal Prince Alfred Hospital and University of Sydney, NSW, Australia.
    53University of Sydney, NSW, Australia.
    54University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    55Deakin University, Geelong, Victoria, Australia.
    56St James's University Hospital, Leeds, UK.
    Abstract

    Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas (TCGA) and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal AnalySiS Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities, and ultimately, improved outcomes for a patient population in need.


    © The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

    KEYWORDS: characterization, evolution, glioma, sequencing, subtypes

    Publikations ID: 29432615
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt